Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2024-02-26 00:00:00 ET · period of report 2024-02-22 · accession 0001628280-24-006984 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-26 | 2024-02-22 | VIR | De Backer Marianne | CEO, Dir | A - Grant | $0.00 | +175.0K | 751.5K | +30% | $0 |
| D | 2024-02-26 | 2024-02-22 | VIR | De Backer Marianne | CEO, Dir | A - Grant | $0.00 | +350.0K | 350.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-22 | A | A | 175,000 | $0.00 | 751,452 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-02-22 | A | A | 350,000 | $0.00 | 350,000 | D | $10.11 · — to 2034-02-21 | 350,000 Common Stock | (F2) 25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter. |